Myasthenia Gravis
Welcome,         Profile    Billing    Logout  
 64 Companies   21 Products   21 Products   23 Mechanisms of Action   207 Trials   10745 News 


«12...8182838485868788899091...136137»
  • ||||||||||  Journal:  To attach great importance to the identification of refractory myasthenia gravis (Pubmed Central) -  Aug 18, 2021   
    Only targeting the poor curative effect from the surface of the intractable state caused indecisive decisions and is difficult to win a success. Therefore, identifying "refractory state" can not only see the essence through the phenomenon, but also apply the right medicine, thereby killing two birds with one stone.
  • ||||||||||  Firdapse (amifampridine) / BioMarin, Catalyst Pharma, Dydo Pharma
    Enrollment change:  Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG (clinicaltrials.gov) -  Aug 18, 2021   
    P3,  N=93, Completed, 
    Therefore, serological examination and early intervention are required for those with abnormal RNS. N=70 --> 93
  • ||||||||||  Journal:  Detecting myasthenia gravis as a cause of unclear dysphagia with an endoscopic tensilon test. (Pubmed Central) -  Aug 17, 2021   
    Application of the Cochran's Q test showed statistically significant heterogeneity among the diagnostic tests, with results indicating FTT performance to be more accurate than the repetitive nerve stimulation results (p  0.99). FTT has excellent clinical properties to be used routinely in the assessment of dysphagia with isolated or predominant pharyngeal muscle involvement allowing rapid and accurate diagnosis of MG.
  • ||||||||||  Clinical, Journal:  Gut bacterial microbiota in patients with myasthenia gravis: results from the MYBIOM study. (Pubmed Central) -  Aug 17, 2021   
    Although the overall diversity and structure of the gut microbiota did not differ between the MG, NIND and CIDP groups, the significant difference in the abundance of Deltaproteobacteria and Faecalibacterium supports the possible role of gut microbiota as a contributor to pathogenesis of MG. Further studies are needed to confirm these findings and to develop possible treatment strategies.
  • ||||||||||  Review, Journal:  Slow-binding inhibitors of acetylcholinesterase of medical interest. (Pubmed Central) -  Aug 14, 2021   
    Through several well-known molecules (e.g. huperzine) and new examples (tocopherol, trifluoroacetophenone and a 6-methyluracil alkylammonium derivative), we show that slow-binding inhibitors of acetylcholinesterase are promising drugs for treatment of neurological diseases such as Alzheimer disease and myasthenia gravis. Moreover, they may be of interest for neuroprotection (prophylaxis) against organophosphorus poisoning.
  • ||||||||||  Clinical, Journal:  Chronic immunoglobulin maintenance therapy in myasthenia gravis. (Pubmed Central) -  Aug 14, 2021   
    Our study results suggest that patients can be successfully transitioned to IVIG and from IVIG to SCIG in the chronic treatment of gMG with reductions in impairments and use of other medications and improvement in overall status with Ig therapy. Prospective, randomized studies are needed to clarify costs and comparative effectiveness.
  • ||||||||||  Clinical, Journal:  Case series of COVID-19 in patients with myasthenia gravis: a single institution experience. (Pubmed Central) -  Aug 14, 2021   
    Our data seem to support the notion that immunosuppressive medication does not seem to result in worse outcomes. Our data also support the notion that intravenous immunoglobulin treatment is safe and should be administered to patients with myasthenia gravis and COVID-19 in case of myasthenia gravis worsening since benefits seem to greatly outweigh the risks.
  • ||||||||||  Clinical, Review, Journal:  SARS-CoV-2 (COVID-19) in Patients with some Degree of Immunosuppression. (Pubmed Central) -  Aug 11, 2021   
    This paper describes risk profiles with temporal information of ICI-induced ADs and proposes certain indicators for deciphering the mechanism of AD onset. Given the little evidence we have so far, the behaviour of SARS-CoV-2 infection in immunosuppressed patients is unclear, but current studies have not shown worse outcomes, except for patients with cancer.
  • ||||||||||  Clinical, Retrospective data, Journal:  Impact of the Surgical Approach to Thymectomy Upon Complete Stable Remission Rates in Myasthenia Gravis: A Meta-analysis. (Pubmed Central) -  Aug 11, 2021   
    A significant difference in the rate of CSR among various surgical approaches for thymectomy in MG was identified only at long-term follow-up, and only between what might be considered the most aggressive approach (extended transsternal thymectomy) and the least aggressive approach (basic transcervical thymectomy). Extended minimally invasive approaches appear to have equivalent CSR rates to extended transsternal approaches and are therefore appropriate in the hands of experienced surgeons.
  • ||||||||||  Journal:  "Fortuitous discovery of a thymoma" (Pubmed Central) -  Aug 11, 2021   
    Extended minimally invasive approaches appear to have equivalent CSR rates to extended transsternal approaches and are therefore appropriate in the hands of experienced surgeons. No abstract available
  • ||||||||||  Clinical, Review, Journal:  SARS-CoV-2 (COVID-19) in patients with some degree of immunosuppression. (Pubmed Central) -  Aug 11, 2021   
    No abstract available Given the little evidence we have so far, the behaviour of SARS-CoV-2 infection in immunosuppressed patients is unclear, but current studies have not shown worse outcomes, except for patients with cancer.
  • ||||||||||  Journal:  Myasthenia Gravis: Which Type of Surgery Is Best? (Pubmed Central) -  Aug 11, 2021   
    Given the little evidence we have so far, the behaviour of SARS-CoV-2 infection in immunosuppressed patients is unclear, but current studies have not shown worse outcomes, except for patients with cancer. No abstract available
  • ||||||||||  Avastin (bevacizumab) / Roche
    Clinical, Review, Checkpoint inhibition, PD(L)-1 Biomarker, IO biomarker:  Myocarditis related to immune checkpoint inhibitors treatment: two case reports and literature review. (Pubmed Central) -  Aug 10, 2021   
    The first case was a 77-year-old male with chordoma, who was treated by third-line sintilimab combined with anlotinib, and presented with symptoms of chest tightness, shortness of breath and upper eyelid ptosis three weeks later...The second case was a 69-year-old female with advanced non-small cell lung cancer, who was treated by pemetrexed combined with bevacizumab and camrelizumab, and presented with palpitations 20 days later...However, the patient developed fatal myasthenia gravis afterwards, with little response to all treatments. These two cases revealed that, early detection and timely intervention, including discontinuation of immune checkpoint inhibitors and initiation of adequate steroid therapy, can reduce morbidity and mortality and improve prognosis.
  • ||||||||||  Enrollment change, Trial completion date, Trial primary completion date:  CMDPROS: Congenital Muscle Disease Study of Patient and Family Reported Medical Information (clinicaltrials.gov) -  Aug 9, 2021   
    P=N/A,  N=4000, Recruiting, 
    MK III TET patients not candidates for primary surgery should be systematically reassessed for resection after induction chemotherapy. N=1000 --> 4000 | Trial completion date: Sep 2019 --> Sep 2029 | Trial primary completion date: Sep 2019 --> Sep 2029
  • ||||||||||  Bridion (sugammadex) / Merck (MSD)
    Clinical, Journal:  Anesthesia and Perioperative Considerations for Patients With Myasthenia Gravis. (Pubmed Central) -  Aug 8, 2021   
    The pathophysiology of myasthenia gravis, cholinergic and myasthenic crises, and perioperative management are discussed; this includes the pharmacology of acetylcholinesterase inhibitors vs sugammadex, extubation criteria, pain management, and risk factors for postoperative myasthenic crisis. Anesthesia recommendations include reversal of nondepolarizing neuromuscular blockade agents with sugammadex, obtaining sufficient spontaneous breathing with absolutely no residual curarization before extubation, limited use of opioids and sedatives, avoidance of routine admission to the intensive care unit, and consideration of peripheral nerve blocks for adjunct pain control.
  • ||||||||||  Journal, Video:  Video-Assisted Thoracic Surgery Thymectomy: Transpleural Approach. (Pubmed Central) -  Aug 7, 2021   
    Thoracic surgeons should be familiar with the principles of the procedure, the anatomy of the region, and surgical strategies for successful thymectomy. The details of transpleural thymectomy are discussed herein.
  • ||||||||||  Journal:  Robot-Assisted Thoracic Surgery Thymectomy. (Pubmed Central) -  Aug 7, 2021   
    The surgical indications of robotic technology are expanding, with advantages including an excellent surgical view and sophisticated manipulation. Herein, we describe technical aspects, considerations, and outcomes of robotic thymectomy.
  • ||||||||||  Journal:  Decreased expression of miR-29 family associated with autoimmune myasthenia gravis. (Pubmed Central) -  Aug 7, 2021   
    It is not clear if the decreased expression of miR-29 subtypes in human MG is a consequence or a causative factor of thymic inflammation. However, our results from the EAMG mouse model indicated that a reduction in miR-29a/b1 may contribute to the pathophysiological process involved in MG by favoring the increased expression of IFN-β and the emergence of pro-inflammatory Th17 cells.
  • ||||||||||  Retrospective data, Journal, IO biomarker:  Nomogram for short-term outcome assessment in AChR subtype generalized myasthenia gravis. (Pubmed Central) -  Aug 7, 2021   
    However, our results from the EAMG mouse model indicated that a reduction in miR-29a/b1 may contribute to the pathophysiological process involved in MG by favoring the increased expression of IFN-β and the emergence of pro-inflammatory Th17 cells. The nomogram achieved an optimal prediction of MSE in AChR subtype gMG patients using the baseline clinical characters.
  • ||||||||||  [VIRTUAL] Meet The Expert Session 03 (Not Included In The Main Event CME/CPD Credit) (Industry 1) -  Aug 6, 2021 - Abstract #WCN2021WCN_535;    
    Among these, we can include the neuromyelitis optic spectrum disorder (NMOSD), a rare disease with still a high therapeutic need to satisfy. Satraliizumab, a monoclonal antibody targeting the IL6 receptor, represents an important therapeutic innovation because it targets a critical proinflammatory cytokine, fundamental for the immunopathogenesis of NMOSD and also for other neuroimmunological pathologies including Myasthenia Gravis, Autoimmune Encephalitis and MOGAD
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma
    [VIRTUAL] Parallel Industry Symposium 01 (Not Included In The Main Event CME/CPD Credit) (Industry 1) -  Aug 6, 2021 - Abstract #WCN2021WCN_414;    
    Session Description: This symposium aims to: -tSpread the knowledge of a pathophysiologic mechanism that not many clinicians know properly, but that is proven to be one of the trigger causes of NMOSD (Neuromyelitis Optica Spectrum Disorder) and gMG (generalized Myasthenia Gravis), two immune mediated rare neurological diseases. -tPresent data for eculizumab on both diseases and highlight innovation in therapeutic environment thanks to the discussion with experts.